×
Chemed Receivables 2010-2024 | CHE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Chemed receivables for the quarter ending December 31, 2024 were
$0.171B
, a
5.7% decline
year-over-year.
Chemed receivables for 2024 were
$0.171B
, a
5.7% decline
from 2023.
Chemed receivables for 2023 were
$0.182B
, a
30.2% increase
from 2022.
Chemed receivables for 2022 were
$0.139B
, a
1.6% increase
from 2021.
View More
Chemed Receivables 2010-2024 | CHE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Chemed receivables for 2024 were
$0.171B
, a
5.7% decline
from 2023.
Chemed receivables for 2023 were
$0.182B
, a
30.2% increase
from 2022.
Chemed receivables for 2022 were
$0.139B
, a
1.6% increase
from 2021.
Related Stocks
Company Name
Market
Cap
Fresenius SE (FSNUY)
$21.5B
Quest Diagnostics (DGX)
$19.2B
DaVita (DVA)
$12.4B
Encompass Health (EHC)
$10.2B
Elanco Animal Health (ELAN)
$5.6B
Option Care Health (OPCH)
$5.5B
RadNet (RDNT)
$4.8B
LifeStance Health (LFST)
$3.1B
Amedisys (AMED)
$3B
Astrana Health (ASTH)
$2.2B
Addus HomeCare (ADUS)
$2.1B
U.S Physical Therapy (USPH)
$1.3B
Aveanna Healthcare Holdings (AVAH)
$968M
Pennant (PNTG)
$927M
Atai Life Sciences (ATAI)
$351M
Bioqual (BIOQ)
$54M
Daxor (DXR)
$35M
Ontrak (OTRK)
$7M
MEDIROM Healthcare Technologies (MRM)
$4M
IMAC Holdings (BACK)
$1M
Psychemedics (PMD)
$0M